Abstract:Objective: To study the effect of treatment with cetirizine and Pinellia Xiexin Decoction on the clinical efficacy and serological parameters of allergic rhinitis. Methods: The clinical data of 147 patients with allergic rhinitis who were treated in our hospital from March 2016 to October 2017 were selected. All patients were divided into control group (n=73) and study group (n=73) according to the random number table method. = 74 cases). Patients in the control group were given cetirizine tablets orally. Patients in the study group were given cetirizine tablets orally and combined with Banxia Xiexin Decoction. T-cell subsets before and after treatment were compared between the two groups of patients. Interleukin-10 (IL- 10), Cytokines and clinical efficacy of transforming growth factor (TGF-β), tumor necrosis factor-α (TNF-α) and serum total IgE. Results: There was no significant difference in T-cell subsets before treatment between the two groups (P>0.05). In the study group, CD4+CD25+ T cells increased significantly after treatment, CD4+ T cells decreased significantly (P<0.05), and CD3+T and CD8+T levels did not change significantly (P>0.05). CD4+ T cells in the control group were significantly lower than before treatment, and CD3+T, CD8+T, and CD4+CD25+ T cells did not change significantly. There was no statistical difference (P>0.05). After treatment, the patients in the study group had statistically significant differences in the levels of CD4+T and CD4+CD25+T compared with the control group (P<0.05). There was no significant difference in serum IgE, TGF-β, IL-10 and TNF-α levels between the two groups before treatment (P>0.05). The levels of IL-10 and TGF-β in the study group were significantly higher than those in the control group, and the levels of TNF-α and IgE were significantly lower than those in the control group. The levels of TGF-β and IL-10 in the two groups after treatment were significantly higher than before treatment, and the levels of TNF-α and IgE were significantly lower than those in the control group, and there were statistical differences (P<0.05). The total effective rate in the control group was 94.52%; the total effective rate in the study group was 95.95%. There was no significant difference in the total effective rate between the two groups (χ2=0.627, P>0.05). The recurrence rate was 31.51% in the control group and 10.81% in the study group. The relapse rate in the study group was significantly lower than that in the control group, and there was a statistically significant difference (χ2=6.637, P<0.05). Conclusion: Cetirizine combined with Banxia Xiexin Decoction has similar effect on alleviating symptoms as cetirizine alone. At the same time, it can promote the normal proportion of different T cell subsets, improve inflammatory cytokines, inflammatory cytokines and IgE content in serum are significantly reduced, reduce the recurrence rate and improve the efficacy of anti-allergic drugs, which can effectively treat allergic rhinitis.
周燕, 崔淑敏, 董萨莎. 西替利嗪联合半夏泻心汤对过敏性鼻炎临床疗效及血清学指标的影响分析[J]. 河北医学, 2019, 25(11): 1894-1898.
ZHOU Yan, CUI Shumin, DONG Sasha. Effect of Cetirizine Combined with Pinellia Xiexin Decoction on Clinical Efficacy and Serological Indexes in the Treatment of Allergic Rhinitis. HeBei Med, 2019, 25(11): 1894-1898.
[1] 王运刚,杨李,崔玉宝.Treg细胞在过敏性免疫应达到和过敏原特异性免疫治疗中的作用机制研究进展[J].中国病原微生物学杂志,2013,8(8):765~769. [2] 黄秋菊,林霞,魏欣,等.特异性免疫治疗对过敏性哮喘合并过敏性鼻炎患者的疗效分析[J].中国临床医生杂志,2019,47(3):327~330. [3] 张治成,杨晓,杨晓刚.自拟醒窍益气汤联合穴位针刺治疗过敏性鼻炎的疗效探讨[J].中国现代医学杂志,2016,26(3):137~140. [4] Guo H,Liu MP.Mechanism of traditional Chinese medicine in the treatment of allergic rhinitis[J].Clin Med,2013,126(4):756~760. [5] Bunyavanich S,Schadt EE,Himes BE,et al.Integrated genome-wide association,coexpression network,and expression single nucleotide polymorphism analysis identifies novel pathway in alldergic rhinitis[J].Bmc Medical Genomics,2014,7(1):1~14. [6] 凌云,杨春悦,杨红梅.氮卓斯汀鼻喷剂联合地氯雷他定治疗过敏性鼻炎65例的疗效评价[J].中国免疫学杂志,2014,30(6):828~830. [7] Eriksson J,Ekerjung L,Sundblad BM,et al.Incidence of allergic rhinitis between 1996 and 2006 in Stockholm[J].European Respiratory Journal,2014,4(Suppl 58):2985.